Abiopharma

New Form EFFECT - Oncology Institute, Inc. Filed: 2025-06-18 AccNo: 9999999995-25-001958 Size: 1 KB

Linde Publishes 2024 Sustainable Development Report

General Announcement: USE OF PROCEEDS FROM THE RIGHTS ISSUE

General Announcement: THE PROPOSED ENTRY INTO A LEASE AGREEMENT AS AN INTERESTED PERSON TRANSACTION

General Announcement: THE PROPOSED ENTRY INTO AN EQUITY CUSTODY AGREEMENT AS AN INTERESTED PERSON TRANSACTION

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

General Announcement: RESOLUTIONS PASSED AT THE 4TH BOARD MEETING FOR FY2025

So-Young Announces Extension of Plan to Implement ADS Ratio Change

Lipella Pharmaceuticals Inc (LIPO) was removed from the list of traded instruments on NASDAQ exchange

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Lipella Pharmaceuticals Inc. - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Lipella Pharmaceuticals Inc. - Common Stock. New value: Lipella Pharmaceuticals Inc. - Common Stock.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Lipella Pharmaceuticals Inc. - Common Stock.

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Q & M Dental Group (Singapore) Limited - Announcement